Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management.
Atypical antipsychotics are associated with fewer movement disorders and a lower risk of tardive dyskinesia than conventional antipsychotics, but are not without side-effects. Metabolic side-effects associated with some of the atypical antipsychotics are a concern for both clinicians and patients. Adverse events related to central nervous system effects, weight gain, and alterations in glucose, lipid, and prolactin levels in patients with depression, bipolar, and anxiety disorders have been reported. Balancing the significant benefits of treatment with these agents against the potential risks of metabolic disturbances and other adverse effects is crucial. Emerging data are making it possible to determine the risk-benefit analysis for specific atypical antipsychotics in individual patients and allow for targeted selection of treatment. A new concept of effectiveness is emerging that attempts to balance adverse effects of treatment with patient quality of life. Patients treated with atypical antipsychotics should have their weight, waist circumference, glucose, and lipids monitored on a regular basis. Monitoring of prolactin levels is not suggested; however, a baseline measurement before initiating treatment can be useful, with subsequent assessment only if a patient demonstrates symptoms. Prevention of weight gain is important. Diet and exercise should be considered for prevention and management, with the use of pharmacologic strategies approached with caution in patients with mood disorders. If a patient is at high risk of developing diabetes, certain pharmacologic agents have been shown to delay the onset of overt diabetes. Once diabetes or dyslipidemia are diagnosed, management should proceed in accordance with approved guidelines for these conditions.
Chue
Pierre
P
Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada.
Kovacs
Chritopher S
CS
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy / Q000453:epidemiology*; D002490:Central Nervous System / Q000187:drug effects; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000139:chemically induced*; D019468:Disease Management; D004347:Drug Interactions; D004361:Drug Tolerance; D005947:Glucose / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D008659:Metabolic Diseases / Q000209:etiology; D008991:Monitoring, Physiologic; D015995:Prevalence; D011388:Prolactin / Q000378:metabolism; D012307:Risk Factors; D012735:Sexual Dysfunction, Physiological / Q000209:etiology; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D011388:Prolactin; D005947:Glucose